Table 1.
Canine clinical trials with NK immune correlates.
| General therapy | Specific therapy | Cancer diagnosis | NK correlates | Method of analysis | References |
|---|---|---|---|---|---|
| Adoptive cell therapy | Autologous NK cell transfer | Osteosarcoma | Number of NK cells | Flow cytometry | (20, 30) |
| Serum cytokines | ELISA | ||||
| Activation markers | Flow cytometry | ||||
| Gene expression | qPCR | ||||
| Cytokine therapy | Inhaled IL-15 | Osteosarcoma, melanoma | Number of NK cells | Flow cytometry | (31, 17, 22) |
| Serum cytokines | ELISA | ||||
| Activation markers | Flow cytometry | ||||
| Gene expression | RNA sequencing | ||||
| Cytotoxicity | Killing assay/flow cytometry | ||||
| Virus-based therapy | Oncolytic virus | Carcinoma, Adenocarcinoma | Number of NK cells | Flow cytometry | (24) |
| Genetically modified HSV | Glioma | Gene expression | RNA seqencing/nanostring | (25) | |
| eCPMV | Inflammatory mammary cancer | Gene expression | RNA seqencing/nanostring | (27) | |
| eCPMV | Mammary cancer | Gene expression | RNA sequencing | (33) | |
| Number of NK cells | Flow cytometry | ||||
| Cellular virotherapy | Various | Number of NK cells | Flow cytometry | (34, 35) | |
| Gene expression | RNA seqencing/CIBERSORT | ||||
| Radio- and chemo-immunotherapy | RT, TRT, IT-IC | Melanoma | Number of NK cells | Flow cytometry | (37) |
| Gene expression | RNA sequencing | ||||
| Chemotherapy, anti-CD20, SMI | B cell lymphoma | Gene expression | RNA sequencing | (38) |
HSV, Herpes Simplex Virus; eCPMV, Empty Cowpea Mosaic Virus; RT, Radiotherapy; TRT, Targeted Radionuclide Therapy; IT-IC, intratumoral immunocytokine; SMI, Small Molecule Inhibitor.